Mink Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

INKT Stock

USD 0.69 0.01 1.47%

Mink Therapeutics financial indicator trend analysis is infinitely more than just investigating Mink Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mink Therapeutics is a good investment. Please check the relationship between Mink Therapeutics Current Deferred Revenue and its Common Stock Shares Outstanding accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mink Therapeutics Current Deferred Revenue account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have pay attention.

The correlation between Mink Therapeutics' Current Deferred Revenue and Common Stock Shares Outstanding is -0.97. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Mink Therapeutics, assuming nothing else is changed. The correlation between historical values of Mink Therapeutics' Current Deferred Revenue and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Mink Therapeutics are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Current Deferred Revenue i.e., Mink Therapeutics' Current Deferred Revenue and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.97

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Mink Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mink Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.Selling General Administrative is likely to drop to about 5.5 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2022	2023	2024 (projected)
Interest Expense	2.4M	253.3K	228.0K	216.6K
Depreciation And Amortization	78.0K	121.7K	204.6K	118.7K

Interest Expense Depreciation And Amortization

Mink Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.59	0.73	0.76	0.91	-0.61	0.79	0.48	0.05	-0.87	-0.45	0.45	1.0	0.48	0.59	1.0	-0.61	0.1	-0.75	-0.14	0.47	0.72	-0.64	0.91	0.44	1.0
Short Long Term Debt Total	0.59		0.91	0.88	0.57	-0.97	0.67	0.83	-0.44	-0.67	-0.86	0.75	0.58	0.83	1.0	0.58	-0.97	0.47	-0.61	0.21	0.61	0.86	-0.43	0.23	0.86	0.57
Other Current Liab	0.73	0.91		0.99	0.62	-0.95	0.68	0.63	-0.4	-0.69	-0.73	0.59	0.72	0.63	0.91	0.72	-0.95	0.47	-0.57	0.3	0.71	0.76	-0.38	0.46	0.65	0.72
Total Current Liabilities	0.76	0.88	0.99		0.65	-0.95	0.7	0.64	-0.4	-0.72	-0.73	0.63	0.75	0.64	0.88	0.75	-0.95	0.5	-0.59	0.27	0.71	0.76	-0.4	0.49	0.64	0.75
Total Stockholder Equity	0.91	0.57	0.62	0.65		-0.59	0.96	0.64	-0.2	-0.99	-0.63	0.54	0.91	0.64	0.57	0.91	-0.59	0.33	-0.95	-0.49	0.14	0.86	-0.9	0.74	0.61	0.9
Other Liab	-0.61	-0.97	-0.95	-0.95	-0.59		-0.69	-0.81	0.53	0.69	0.87	-0.78	-0.6	-0.81	-0.97	-0.6	1.0	-0.59	0.61	-0.23	-0.64	-0.84	0.43	-0.26	-0.83	-0.6
Net Tangible Assets	0.79	0.67	0.68	0.7	0.96	-0.69		0.75	-0.47	-0.98	-0.8	0.61	0.8	0.75	0.67	0.8	-0.69	0.56	-0.98	-0.49	0.07	0.93	-0.93	0.53	0.75	0.78
Property Plant And Equipment Net	0.48	0.83	0.63	0.64	0.64	-0.81	0.75		-0.52	-0.75	-0.94	0.95	0.47	1.0	0.83	0.47	-0.81	0.58	-0.77	-0.21	0.26	0.92	-0.68	0.08	0.99	0.46
Current Deferred Revenue	0.05	-0.44	-0.4	-0.4	-0.2	0.53	-0.47	-0.52		0.34	0.75	-0.41	0.05	-0.52	-0.44	0.05	0.53	-0.97	0.41	0.19	0.16	-0.49	0.4	0.39	-0.56	0.07
Net Debt	-0.87	-0.67	-0.69	-0.72	-0.99	0.69	-0.98	-0.75	0.34		0.75	-0.65	-0.87	-0.75	-0.67	-0.87	0.69	-0.45	0.97	0.45	-0.17	-0.93	0.91	-0.63	-0.73	-0.86
Retained Earnings	-0.45	-0.86	-0.73	-0.73	-0.63	0.87	-0.8	-0.94	0.75	0.75		-0.83	-0.44	-0.94	-0.86	-0.44	0.87	-0.78	0.78	0.19	-0.21	-0.92	0.68	-0.03	-0.96	-0.43
Accounts Payable	0.45	0.75	0.59	0.63	0.54	-0.78	0.61	0.95	-0.41	-0.65	-0.83		0.44	0.95	0.75	0.44	-0.78	0.52	-0.63	-0.08	0.4	0.8	-0.52	0.09	0.89	0.44
Cash	1.0	0.58	0.72	0.75	0.91	-0.6	0.8	0.47	0.05	-0.87	-0.44	0.44		0.47	0.58	1.0	-0.6	0.1	-0.76	-0.16	0.45	0.71	-0.65	0.91	0.44	1.0
Non Current Assets Total	0.48	0.83	0.63	0.64	0.64	-0.81	0.75	1.0	-0.52	-0.75	-0.94	0.95	0.47		0.83	0.47	-0.81	0.58	-0.77	-0.21	0.26	0.92	-0.68	0.08	0.99	0.46
Long Term Debt	0.59	1.0	0.91	0.88	0.57	-0.97	0.67	0.83	-0.44	-0.67	-0.86	0.75	0.58	0.83		0.58	-0.97	0.47	-0.61	0.21	0.61	0.86	-0.43	0.23	0.86	0.57
Cash And Short Term Investments	1.0	0.58	0.72	0.75	0.91	-0.6	0.8	0.47	0.05	-0.87	-0.44	0.44	1.0	0.47	0.58		-0.6	0.1	-0.76	-0.16	0.45	0.71	-0.65	0.91	0.44	1.0
Net Receivables	-0.61	-0.97	-0.95	-0.95	-0.59	1.0	-0.69	-0.81	0.53	0.69	0.87	-0.78	-0.6	-0.81	-0.97	-0.6		-0.59	0.61	-0.23	-0.65	-0.84	0.43	-0.26	-0.82	-0.6
Common Stock Shares Outstanding	0.1	0.47	0.47	0.5	0.33	-0.59	0.56	0.58	-0.97	-0.45	-0.78	0.52	0.1	0.58	0.47	0.1	-0.59		-0.49	-0.21	-0.07	0.55	-0.48	-0.24	0.59	0.08
Non Current Liabilities Total	-0.75	-0.61	-0.57	-0.59	-0.95	0.61	-0.98	-0.77	0.41	0.97	0.78	-0.63	-0.76	-0.77	-0.61	-0.76	0.61	-0.49		0.6	0.02	-0.93	0.97	-0.49	-0.77	-0.74
Inventory	-0.14	0.21	0.3	0.27	-0.49	-0.23	-0.49	-0.21	0.19	0.45	0.19	-0.08	-0.16	-0.21	0.21	-0.16	-0.23	-0.21	0.6		0.78	-0.3	0.76	-0.11	-0.19	-0.13
Other Current Assets	0.47	0.61	0.71	0.71	0.14	-0.64	0.07	0.26	0.16	-0.17	-0.21	0.4	0.45	0.26	0.61	0.45	-0.65	-0.07	0.02	0.78		0.25	0.24	0.38	0.24	0.47
Other Stockholder Equity	0.72	0.86	0.76	0.76	0.86	-0.84	0.93	0.92	-0.49	-0.93	-0.92	0.8	0.71	0.92	0.86	0.71	-0.84	0.55	-0.93	-0.3	0.25		-0.83	0.37	0.93	0.7
Total Liab	-0.64	-0.43	-0.38	-0.4	-0.9	0.43	-0.93	-0.68	0.4	0.91	0.68	-0.52	-0.65	-0.68	-0.43	-0.65	0.43	-0.48	0.97	0.76	0.24	-0.83		-0.42	-0.67	-0.63
Net Invested Capital	0.91	0.23	0.46	0.49	0.74	-0.26	0.53	0.08	0.39	-0.63	-0.03	0.09	0.91	0.08	0.23	0.91	-0.26	-0.24	-0.49	-0.11	0.38	0.37	-0.42		0.04	0.91
Property Plant And Equipment Gross	0.44	0.86	0.65	0.64	0.61	-0.83	0.75	0.99	-0.56	-0.73	-0.96	0.89	0.44	0.99	0.86	0.44	-0.82	0.59	-0.77	-0.19	0.24	0.93	-0.67	0.04		0.43
Total Current Assets	1.0	0.57	0.72	0.75	0.9	-0.6	0.78	0.46	0.07	-0.86	-0.43	0.44	1.0	0.46	0.57	1.0	-0.6	0.08	-0.74	-0.13	0.47	0.7	-0.63	0.91	0.43

Click cells to compare fundamentals

Mink Therapeutics Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mink Stock Analysis

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mink Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Common Stock Shares Outstanding

Mink Therapeutics fundamental ratios Correlations

Mink Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Mink Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Long Term Debt	+ 1.0	Short Long Term Debt Total
Net Receivables	+ 1.0	Other Liab
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net

Net Debt	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Net Debt	- 0.98	Net Tangible Assets
Net Receivables	- 0.97	Long Term Debt
Common Stock Shares Outstanding	- 0.97	Current Deferred Revenue
Long Term Debt	- 0.97	Other Liab